Studies have demonstrated that siRNA‐mediated silencing of genes such as AR, B‐cell lymphoma 2 (BCL2), and Enhancer of Zeste Homolog 2 (EZH2), as well as miRNA modulation (e.g., restoration of tumor‐suppressive miRNAs like miR‐34a or inhibition of oncogenic miRNAs like miR‐21), significantly inhibits tumor cell proliferation, induces apoptosis, and improves therapeutic outcomes [50, 51, 52, 53]. Here, BCL2 is linked to neoplasm.